Funded Projects

The Chad Carr Pediatric Brain Tumor Center is committed to pushing the limits of what is known about pediatric brain tumors, and advancing treatment for children with these diseases.

Thanks to contributions to the U-M Chad ToughFund and the incredible efforts of the ChadTough Foundation, the Chad Carr Pediatric Brain Tumor Center has established a Proof of Principal Research Collaboration (P3RC) Award.

P3RC awards are granted to projects in our priority research areas of drug delivery, device deployment, clinical trials, cellular therapy and immunotherapeutics, and are designed to bring University of Michigan investigators from complimentary fields together to work on research strategies and approaches to cure DIPG.  All funding recipients agree to share data with other Chad Carr Pediatric Brain Tumor Center research faculty.

Proposals for P3RC Awards are accepted on a rolling basis, are reviewed, then presented to the CCPBTC Advisory Committee for funding determination. Funding awards are determined through peer-review using internal and, where appropriate, external reviews to ensure funds support innovative projects that can be feasibly accomplished.

View the current RFA for proposal guidelines and submission instructions.  Applications are accepted through Competition Space.  The CCPBTC Advisory Committee meets quarterly (Oct, Jan, Apr, Jul) to review proposals. For additional information or questions regarding the application process, please contact Jackie Torres in the Pediatrics Research Office at jjtorres@umich.edu or at 734-763-9150.

2018 Funded Projects

Targeting metabolic reprogramming in H3K27M DIPGs
Cellular Therapy
Principal Investigator: Sriram Venneti, MD, PhD
U-M Co-Investigators: Costas Lyssiotis, PhD; Carl Koschmann, MD
Collaborators:  Michelle Monje, MD, PhD, Stanford University; Sophia Lunt, PhD, Michigan State University

A Phase 2 Study of ONC201 for Children and Young Adults with Gliomas Harboring H3K27M Mutation
Clinical Trial
Principal Investigator: Carl Koschmann, MD
U-M Co-Investigators: Patricia Robertson, MD; Marcia Leonard, NP; Rajen Mody, MD; Hugh Garton, MD; Abraham Van Der Spek, MD; Hemant Parmar, MD; Yue Cao, PhD; Bernard Marini, PharmD; Lili Zhao, PhD

Uncovering novel DNA-damage repair pathway targets in DIPG
Clinical Trial / Drug delivery/device development
Principal Investigator: Carl Koschmann, MD
U-M Co-Investigators: Meredith Morgan, MD; Dan Lawrence, PhD; Ted Lawrence, MD, PHD; Alnawaz Rehemtulla, PhD; Sriram Venneti, MD, PhD
Collaborator:Timothy Phoenix, PhD, Cincinnati Children's Hospital Medical Center

Therapeutic targeting of the disrupted metabolic state in DIPG to induce ferroptotic cell death
Cellular Therapy
Principal Investigator: Costas Lyssiotis, PhD
U-M Investigator: Sriram Venneti, MD, PhD

2017 Funded Projects

Investigating a novel method of opening the blood brain barrier for treatment of DIPG

Drug Delivery Research
Principal Investigator: Daniel Lawrence, PhD
U-M Co-Investigators: Enming Su, PhD, Carl Koschmann, MD, Sriram Venneti, MD, PhD

H3K27M Interactome Mapping to Discover Novel DIPG Therapeutic Targets

Cellular Therapy Research
Principal Investigator: Sriram Venneti, MD, PhD
U-M Co-Investigators: Jean-Francois Rual, PhD, and Alexey I. Nesvizhskii, PhD
Collaborators: Michelle Monje, MD, PhD, Stanford University

Metabolic approaches to combat DIPG

Cellular Therapy Research
Principal Investigator: Sriram Venneti, MD, PhD
U-M Investigator: Costas Lyssiotis PhD
Collaborators: Michelle Monje, MD, PhD, Stanford University

CSF Digital Droplet PCR Analysis for DIPG Diagnosis and Therapy Response

Clinical Trial
Principal Investigator: Carl Koschmann, MD
Co-Investigators: Robert Dickson, MD, Benjamin Singer, MD, PhD

A Phase 2 Study of Pazopanib in Combination with Everolimus for Children with Recurrent DIPG Harboring PDGFR/FGFR Alterations

Clinical Trial
Principal Investigator: Carl Koschmann, MD
U-M Co-Investigators: Patricia Robertson, MD, Marcia Leonard, NP, Rajen Mody, MD MS, Hugh Garton, MD, Abraham Van Der Spek, MD, Hemant Parmar, MD, Yue Cao, PhD, Bernard Marini, PharmD, Lili Zhao, PhD

Comprehensive Genomic Characterization of DIPG to Guide Personalized Genomically Driven Therapy

Clinical Trial
Principal Investigator: Rajen Mody, MD, MS
U-M Co-Investigators: Arul Chinnaiyan, MD, PhD, Carl Koschmann, MD, Patricia Robertson, MD, Hugh Garton, MD, Marcin Cieslik, PhD, Sriram Venneti, MD, PhD

2016 Funded Projects - ChadTough Fund

Exploring role of ACVR1 and HIST1H3B Mutations in DIPG in vivo in Preclinical Mouse Models: Uncovering Novel Therapeutic Targets

Principal Investigator: Maria G. Castro
Co-Principal Investigator: Pedro R. Lowenstein